Heparin-Coated Solid Support for Extracellular Vesicle Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating extracellular vesicles (EVs) are inefficient, often requiring expensive equipment, are laborious, and result in co-sedimentation of protein aggregates and nucleic acids, making it difficult to achieve large-scale isolation and maintain EV integrity.
Innovation Solution
The use of heparin-coated solid supports, such as beads or affinity chromatography columns, to bind and separate EVs from biological samples through centrifugation or magnetization, allowing for efficient isolation and purification of EVs while minimizing contamination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If differential and high speed ultracentrifugation is used to isolate EVs, then EVs can be separated from biological samples, but protein aggregates and nucleic acids co-sediment with EVs, reducing purification quality
Solution Approach 1:
The patent introduces an intermediary substance (magnetic beads coated with anti-TSG101 antibody) that mediates the separation of EVs from contaminants. The magnetic beads specifically bind to EVs through the antibody-EV interaction, allowing selective isolation without co-sedimentation of protein aggregates and nucleic acids that occur in traditional ultracentrifugation methods.
Solution Approach 2:
The patent replaces the mechanical separation system of ultracentrifugation (which relies on density-based sedimentation) with a biochemical affinity system using magnetic beads. This substitution allows for specific antigen-antibody mediated separation that is not limited by density differences, thereby improving purification quality while maintaining isolation efficiency.
2Manufacturing precision
If density gradient separation is used to isolate EVs, then EVs can be separated based on density, but the process is lengthy and laborious with low yield
Solution Approach 1:
The patent replaces the lengthy density gradient separation process with a magnetic bead-based affinity capture system. The magnetic beads coated with anti-TSG101 antibody directly bind to EVs in a single step, eliminating the need for multiple density gradient layers and extended centrifugation times, thereby dramatically improving isolation efficiency while maintaining separation precision.
Solution Approach 2:
The patent applies preliminary action by pre-coating magnetic beads with anti-TSG101 antibody before exposure to the biological sample. This pre-preparation of the magnetic beads with the specific antibody ensures immediate and specific binding to EVs upon contact with the sample, streamlining the isolation process and eliminating the need for complex gradient formation and multiple separation steps.
3Manufacturing precision
If proprietary commercial kits are used to isolate EVs, then EVs can be isolated with some purification, but large scale isolation is not allowed and disease-specific antibodies are required
Solution Approach 1:
The patent achieves universality by using anti-TSG101 antibody-coated magnetic beads that can isolate EVs from multiple different biological samples (cell culture media, serum, plasma, urine, CSF) and from various cell types. This single platform method replaces the need for disease-specific antibodies required by commercial kits, making the method broadly applicable to different EV isolation needs while maintaining high purification quality.
Solution Approach 2:
The patent employs magnetic beads as disposable, non-recoverable isolation tools that can be used once and then discarded. This approach eliminates the need for expensive, complex commercial kit components and allows for scalable isolation without the limitations of proprietary systems. The magnetic beads provide a cost-effective, versatile platform that can be easily adapted to different sample types and scales.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables rapid, efficient, and high-yield isolation of EVs with minimal contamination, maintaining their functional integrity and RNA profile, and allows for their potential use in therapeutic agent delivery and biomarker analysis.
Implementation Method 1
heparin can directly bind to the surface of EVs
Implementation Method 2
separating the solid support-bound EV from the sample, e.g., by centrifugation
Implementation Method 3
separating the solid support-bound EV from the sample, e.g., by centrifugation, elution, magnetization of the sample
Data Source
AI summary
The specification provides methods for isolating extracellular vesicles. Extracellular vesicles can be efficiently isolated, e.g., from biological fluids or cell culture media, using a heparin-coated solid support.